Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Alcohol-related liver disease

Shaping new paths in clinical trial design to address alcohol use disorders and alcohol-associated liver disease

An expert panel has proposed 28 recommendations for the design and conduct of clinical trials for alcohol use disorders and alcohol-associated liver disease. This field has a scarcity of clinical trials, despite alcohol abuse and alcohol-related liver disease being one of the greatest causes of morbidity and mortality worldwide.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Summary of the new expert recommendations for designing clinical trials to address alcohol use and alcohol-associated liver disease.


  1. Hofer, B. S. et al. Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis. Clin. Gastroenterol. Hepatol. 21, 2308–2317.e7 (2023).

    Article  PubMed  Google Scholar 

  2. Lackner, C. et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. J. Hepatol. 66, 610–618 (2017).

    Article  PubMed  Google Scholar 

  3. Lee, B. P. et al. Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement. Nat. Rev. Gastroenterol. Hepatol. (2024).

  4. National Institute on Alcohol Abuse and Alcoholism. Alcohol’s effects on health: research-based information on drinking and its impact. NIH (2023).

  5. Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78, 1966–1986 (2023).

    Article  PubMed  Google Scholar 

  6. Akhavan Rezayat, A. et al. Association between smoking and non-alcoholic fatty liver disease: a systematic review and meta-analysis. SAGE Open Med. 6, 2050312117745223 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Singal, A. K., Leggio, L. & DiMartini, A. Alcohol use disorder in alcohol-associated liver disease: two sides of the same coin. Liver Transplant. 30, 200–212 (2024).

    Article  Google Scholar 

  8. Oberoi, M., Noor, Md. S. & Abdelfatah, E. The multidisciplinary approach and surgical management of GE junction adenocarcinoma. Cancers 16, 288 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Schomerus, G. et al. The stigma of alcohol-related liver disease and its impact on healthcare. J. Hepatol. 77, 516–524 (2022).

    Article  PubMed  Google Scholar 

  10. Mackowiak, B., Fu, Y., Maccioni, L. & Gao, B. Alcohol-associated liver disease. J. Clin. Invest. 134, e176345 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Helena Cortez-Pinto.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Serrazina, J., Cortez-Pinto, H. Shaping new paths in clinical trial design to address alcohol use disorders and alcohol-associated liver disease. Nat Rev Gastroenterol Hepatol (2024).

Download citation

  • Published:

  • DOI:


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research